SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor.

Marie-Amelie HengArnauld VerschuurAudrey AscheroAlexia DabadieElisabeth JouvePascal ChastagnerPierre LeblondIsabelle AertsBénédicte De LucaNicolas André

Published in: Pediatric blood & cancer (2019)

This MC has no activity in BS and limited though interesting activity in NBL with some patients being stable for > 1 year. It is not possible to conclude activity in STS and Misc.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
randomized controlled trial
prognostic factors
open label
adverse drug
patient reported